Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00762424 · ClinicalTrials.gov registry record · NA
Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis
A NA study, sponsored by WellSpan Health.
- Completed
- Registry status
- NA
- Development phase
- 53
- Enrollment target
NCT00762424 is a NA study that has completed, run by WellSpan Health. The registered enrollment target is 53 participants.
The verdict
NCT00762424, a NA study, has completed, sponsored by WellSpan Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 53 participants
- Enrollment target
Study Summary
Tamsulosin (Flowmax)is approved by the FDA for the treatment for enlarged prostate. Several studies regarding the use of Tamsulosin for the treatment of lower kidney stones have been carried out in the non-Emergency Department setting. This study will compare Tamsulosin 0.4 mg with placebo in regards to rate and time of stone passing and will also look at amount of pain. The purpose of this study is to compare the usefulness of Tamsulosin versus placebo on time to stone passage and pain relief in Emergency Department patients with kidney stones.
Interventions
- DRUG placebo
- DRUG Flowmax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2007-06 |
| Est. Completion | 2011-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00762424
The ClinicalTrials.gov registry entry for NCT00762424 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is WellSpan Health, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00762424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00762424 about?
NCT00762424 is a clinical study titled "Effect of Tamsulosin on Stone Expulsion and Pain Resolution in ED Patients With Ureterolithiasis". Tamsulosin (Flowmax)is approved by the FDA for the treatment for enlarged prostate. Several studies regarding the use of Tamsulosin for the treatment of lower kidney stones have been carried out in the non-Emergency Department setting. This study will compare Tamsulosin 0.4 mg with placebo in regard...
What is the current status of trial NCT00762424?
This trial is currently completed. It is a NA study. The enrollment target is 53 participants. The study started on 2007-06. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00762424?
The interventions under investigation include: placebo (DRUG), Flowmax (DRUG).
Who is sponsoring clinical trial NCT00762424?
This trial is sponsored by WellSpan Health, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.